Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
      • TNX-3600
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Long COVID, Chronic Migraine, and Major Depressive Disorder. Please visit Clinical Trials.

Op-Eds

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Tonix in the News
  • Press Releases
  • IR Events
  • Email Alerts
  • Op-Eds
The Medicine Maker | Dec 14, 2022

Big Diseases in a Small World

Infection Control Today | Dec 7, 2022

How We Can Wage a Smarter Defense Against Future Pandemics

LinkedIn | Sep 28, 2022

Yes, We Can "Stop the Spread"

Contagion Live | Aug 22, 2022

Our Price for Not Aiming Higher: Long COVID Is Here to Stay

Life Science Leader | Aug 12, 2022

What Should We Do About Monkeypox?

Washington Post | Jul 17, 2022

The United States should resume funding for next-generation vaccines

Daily Montanan | Jun 18, 2022

America can’t get caught flat-footed on pandemics again

PharmExec.com | Jun 14, 2022

Why Are We Surrendering to COVID?

The Hill | May 9, 2022

No time to wait on development of second-generation vaccines

LinkedIn | Dec 30, 2021

Why is COVID Still Winning?

NJ.com | Nov 30, 2021

The Omicron variant, childhood infections and long COVID: It’s a bigger war now

LinkedIn | Sep 28, 2021

We Need to Help COVID-19 Long Haulers Now

Washington Examiner | Mar 30, 2021

The Path to Lasting COVID-19 Immunity

Washington Examiner | Sep 23, 2019

We need more than awareness to defeat the epidemic of veteran suicides

Fox News | May 18, 2019

Seth Lederman: Our vets fought to protect our freedom. We must fight for their freedom from PTSD and suicide

Washington Examiner | Jan 1, 2019

Military-related PTSD: Our year to act

rss_feed RSS
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.